abstract |
The present invention relates to novel 2-arylimino-2,3-dihydrothiazole derivatives of the formula I which have good affinity for certain somatostatin receptor subtypes and are therefore used in the treatment of pathological conditions or diseases involving one or more somatostatin receptors , eg: acromegaly, pituitary adenomas, endocrine gastroenteropancreatic tumors including carcinoid or gastrointestinal bleeding. |